NASDAQ : VALN

Valneva SE — News

$5.3 USD

$0 (0.0%)

Volume
49.08K
Average Volume
29.61K
Market Capitalization
$502.56M
P/E Ratio
-3.11
Dividend Yield
0.00%
Price Target
$11.00
Year High
$12.25
Year Low
$4.75
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$2.14
Source Headline
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026

Lyon (France), July 22, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first half 2026 financial results on Thursday, August 13, 2026. The Company will host a live webcast beginning at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update.

globenewswire.com - 2026-07-22 11:45:00

Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript

Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript

seekingalpha.com - 2026-06-25 13:52:09

Valneva Announces Successful Outcome of its Annual General Meeting

Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that shareholders approved all resolutions recommended by the Board of Directors at the Company's Annual General Meeting (AGM), held earlier today in Lyon, France. Key resolutions adopted included the approval of the 2025 financial statements, renewal of authorizations granted to the Board of Directors regarding the Company's share capital, and the transfer of Valneva's registered office to Lyon following the closure of its Nantes site.

globenewswire.com - 2026-06-25 11:45:00

Valneva Announces Availability of Documentation for its Annual General Meeting

Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Annual General Meeting (“the Meeting”) to be held on June 25, 2026 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France).

globenewswire.com - 2026-06-04 01:00:00

Valneva to Participate at U.S. and European Investor Conferences in June

Lyon (France), May 28, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2026.

globenewswire.com - 2026-05-28 11:45:00

Valneva to Participate at U.S. and European Investor Conferences in June

Lyon (France), May 28, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2026.

globenewswire.com - 2026-05-28 11:45:00

Valneva annonce sa participation à des conférences investisseurs aux États-Unis et en Europe

Lyon (France), le 28 mai 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante participeront, en juin 2026, à plusieurs conférences aux États-Unis et en Europe, au cours desquelles ils feront des présentations et rencontreront des investisseurs institutionnels.

globenewswire.com - 2026-05-28 11:45:00

Valneva Q1 Earnings Call Highlights

Valneva NASDAQ: VALN reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer.

marketbeat.com - 2026-05-13 15:12:54

Valneva SE (VALN) Q1 2026 Earnings Call Transcript

Valneva SE (VALN) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-13 13:01:08

Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Lyon (France), May 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ended March 31, 2026, provided key corporate updates, and updated its 2026 financial guidance. The condensed consolidated interim financial results are available on the Company's website (Financial Reports – Valneva).

globenewswire.com - 2026-05-13 01:00:00

Get VALN Insider Trade Alerts

VALN Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$0.00

0 analysts

Last Year

$12.50

2 analysts

All Time

$16.50

4 analysts

VALN Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-04-22 Goldman Sachs Downgrade Neutral Sell